Short answer
LivaNova PLC (LIVN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $393M (up 9.9% year over year) with net income of $34M.
Q3 2026 key financials · XBRL
- Revenue
- $393M
- +9.9% YoY · +0.7% QoQ
- Net income
- $34M
- +28.0% YoY · −68.4% QoQ
- Operating margin
- 7.2%
- Gross margin
- 67.4%
- EPS (diluted)
- $0.60
- +20.0% YoY · −68.9% QoQ
Source: XBRL data from the LivaNova PLC (LIVN) Q3 2026 10-Q on SEC EDGAR. USD.
LivaNova PLC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $393.1M, up 9.9% YoY from $357.8M
- Gross margin 67.4% vs 68.4% YoY; operating margin 7.2% vs 15.1%
- Best segment Neuromodulation: revenue $166.1M, up 11.1%; income $62.1M, up 10.6%
- Worst segment Cardiopulmonary: income $7.6M, down 69.3% despite revenue up 10.9% to $225.3M
- Cash $563.5M vs $635.6M; nine-month operating cash flow $155.5M vs $171.9M, debt repayment $95.9M
Risk Factors
- No material changes from the 2025 Form 10-K
- Product liability and medical-device regulatory compliance risks remain significant
- Competition and healthcare-market pressures continue affecting near-term performance
- Liquidity, debt, and foreign-currency exposure remain carried-forward financial risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LivaNova PLC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.